Summary & Overview
HCPCS G9096: Esophageal Cancer Disease-Status Assessment
HCPCS Level II code G9096 designates an oncology disease-status assessment for esophageal cancer limited to predominant adenocarcinoma or squamous cell carcinoma histology, where initial staging is T1–T3, N0–N1 or NX and there is no evidence of progression, recurrence, or metastasis. The code is intended for use within a Medicare-approved demonstration project and signals a focused staging/assessment encounter prior to neo-adjuvant therapy when applicable. Nationally, a clear billing pathway for initial disease-status documentation supports quality measurement and care coordination in oncology programs and demonstration efforts.
Key payers in scope for this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find clinical context about the code’s intended use, the expected service setting, and what the code represents for initial staging of localized esophageal cancer. The publication summarizes policy implications for demonstration projects, common billing considerations, and where data limitations exist.
This report is national in scope and provides benchmarks and policy context relevant to payers and provider organizations engaged in oncology staging and demonstration projects, along with operational notes on typical sites of service and service type.
Billing Code Overview
HCPCS Level II code G9096 describes an oncology disease-status assessment for esophageal cancer when the predominant histology is adenocarcinoma or squamous cell carcinoma. The code applies when the extent of disease is initially established as T1–T3, N0–N1 or NX, prior to any neo-adjuvant therapy if used, and there is no evidence of disease progression, recurrence, or metastases. This designation is intended for use in a Medicare-approved demonstration project.
Service type: Oncology disease-status assessment (initial staging/assessment)
Typical site of service: Hospital outpatient oncology clinic, cancer center, or ambulatory surgical/diagnostic setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 64-year-old patient with biopsy-proven esophageal adenocarcinoma is evaluated at a tertiary cancer center participating in a Medicare-approved demonstration project. Staging workup (endoscopic ultrasound, CT chest/abdomen, and PET as indicated) established the primary tumor as T2 with regional nodal status N0–N1 and no distant metastases. The multidisciplinary tumor board documents initial extent of disease as t1-t3, n0-n1 or nx prior to any neo‑adjuvant therapy. The oncology clinic documents disease status using code G9096 to indicate limited esophageal cancer (adenocarcinoma or squamous cell carcinoma predominant) with no evidence of progression, recurrence, or metastases at the baseline assessment for the demonstration project. Typical workflow includes: initial diagnostic staging by gastroenterology and radiology, pathology confirmation, tumor board staging and documentation, entry of disease status into the demonstration project registry, and periodic reassessment after neo‑adjuvant therapy or surveillance. Typical site of service: hospital outpatient clinic, cancer center ambulatory clinic, or multidisciplinary tumor board setting where baseline disease status is documented for program reporting.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | When no modifiers apply to the service as reported under . |